Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Let's just get some volume here ok
Me thinks, friends wanting to buy in heere!!
LOL..Are you sure there are only 2 puzzle pieces missing??
Something is telling me a few more things are lacking here. LOL
Many of us looked for the extension rate and could not find anything myself included. Good point! Companies hardly do ever challenge NASDAQ regarding a delisting, which speaks volumes about PPHM IMO, I know you won't agree to that!
And I did not say it is some big accomplishment and they must have really shown Nasdaq something to get the 30 days........Reality is, PPHM did get 30 days and Nasdaq approved of that based on what ever it was convinced them and for right now, that's all that matters.
Well said horselover agree!
Agarn are you saying no one ever was NOT granted an extension??
ADD: Under similar circumstances.
Can anyone here name to me one company who has received an extension such as this under similar circumstances?
If NASDAQ allowed this action, it is under an agreement that satisfies their (NASDAQ) standards and justifies cause for such action. I am confident the ruling was in the best interest of all concerned including mankind. We will be told when it is time.
That is an absolute IMO biopharm
Information appears to be released slowly, methodically and in a need to know basis. And in my opinion there is no rush to bolster themselves to raise the pps. Actually this proves to me others are involved and a need to proceed in this manner is in the best interest of the BOD and share holders. We may not agree (as we age) however I do believe we are very close to becoming a force to reckoned with and this alone will keep us in the game perhaps for generational wealth.......I read this statement on this very board!!
Good to see you take an active roll in the co. you so actively invest in.
Your comments are so uplifting and familiar. Sounds like you are loading up the vessel as well.
A good friend from Montana speaks much like yourself a real good bud he is. He flew in from Butte to Chicago for ASCO weekend.
Just flying by in a different part of our world today and seeing many negative post and some great informational posts as well.....I could give one of my usual one liners, but instead I'll comment on the after market, since no one else did :.)
Seeing 400 sh traded @ 19:05:49 @.53 down 4.44%.........that is all!
Good post
Good wine...Perhaps we share one day.
This may be it..TS
May 01, 2017 08:00 ET
MilliporeSigma's Mobius® 2,000-liter Single-use Bioreactors to Expand Avid Bioservices' Manufacturing Capabilities
Technology allows Avid to meet increased demand for clinical and commercial manufacturing services at Myford facility
Industry-leading design provides flexibility, scalability, ease-of-use
BILLERICA, MA--(Marketwired - May 1, 2017) - MilliporeSigma and Avid Bioservices, Inc., today announced that Avid will upgrade its Myford clinical and commercial manufacturing facility with multiple Mobius® 2000-liter single-use bioreactors from MilliporeSigma. The new bioreactors, to be installed in mid-2017, provide Avid with the latest technology while expanding the company's manufacturing capacity. Avid is a wholly owned subsidiary of Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) (NASDAQ: PPHMP).
"An integral part of our complete single-use offering, Mobius® bioreactors help companies like Avid move toward the goal of fully disposable manufacturing," said Udit Batra, Member of the Executive Board, Merck KGaA, Darmstadt, Germany and CEO, MilliporeSigma. "We will continue to support Avid as it upgrades its facility to help customers advance molecules into the clinic and to market so that patients have better access to life-enhancing drugs."
Single-use technology is becoming increasingly popular in the industry. The market for single-use bioprocessing is estimated to reach $5.9 billion by 2024, according to Transparency Market Research. More than 90 percent of biopharma facilities use single-use technologies, according to Bioplan Associates.
"We ran a competitive process and chose the MilliporeSigma Mobius® 2,000-liter single-use bioreactor system because it offers technical and ease of use advantages over competing single-use systems," said Steven W. King, President, Avid Bioservices. "The confidence in the choice has only been further reinforced by our experience to date with the Mobius® system up to the 1000-liter scale as part of a pilot program. Adding the Mobius® technology to expand Avid's Myford biomanufacturing capacity highlights our commitment to offer customers the latest single-use equipment and flexible solutions." King added that the first 2,000-liter pilot batch is planned for later this month.
Traditionally, biopharmaceutical companies used large stainless steel vessels in multi-story buildings, requiring substantial investment and rigorous setup. With single-use disposable equipment, customers get improved batch turnaround times, reduced risk of product cross-contamination, decreased capital costs and have less equipment to clean. MilliporeSigma's single-use technology helps accelerate customers' molecules to market, improve productivity, and ensure supply continuity.
"The planned installation of MilliporeSigma's Mobius® 2000-liter bioreactors opens new opportunities for current and future Avid customers who require greater manufacturing capacity," King added. "We have already secured customer commitments for the 2,000-liter capacity as soon as it is installed in our Myford facility and believe the advanced technology it offers will be a key factor in continuing to grow our Contract Development and Manufacturing Organization business."
Avid has installed the appropriate systems at its Myford facility in Orange County, California to allow integration of MilliporeSigma's Mobius® bioreactors. The 40,000-square foot Myford facility was designed to accommodate a fully disposable biomanufacturing process for late Phase III clinical and commercial biologics production. The facility can operate multiple bioreactors simultaneously, improving manufacturing capacity and efficiency.
MilliporeSigma's Mobius® stirred tank bioreactor portfolio, with sizes ranging from 3- to 2000-liters, offers flexibility, scalability and ease-of-use. Mobius® bioreactors support GMP production and allow customers to optimize, streamline and accelerate drug development and production.
About Avid Bioservices, Inc.
Avid Bioservices, a wholly owned subsidiary of Peregrine Pharmaceuticals, provides a comprehensive range of process development, high quality cGMP clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries. With over 15 years of experience producing monoclonal antibodies and recombinant proteins in batch, fed-batch and perfusion modes, Avid's services include cGMP clinical and commercial product manufacturing, purification, bulk packaging, stability testing and regulatory strategy, submission and support. The company also provides a variety of process development activities, including cell line development and optimization, cell culture and feed optimization, analytical methods development and product characterization. For more information about Avid, please visit www.avidbio.com.
About Peregrine Pharmaceuticals, Inc.
Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company committed to improving the lives of patients by delivering high quality pharmaceutical products through its contract development and manufacturing organization (CDMO) services and through advancing and licensing its investigational immunotherapy and related products. Peregrine's in-house CDMO services, including cGMP manufacturing and development capabilities, are provided through its wholly-owned subsidiary Avid Bioservices, Inc. (www.avidbio.com), which provides development and biomanufacturing services for both Peregrine and third-party customers. The company is also working to evaluate its lead immunotherapy candidate, bavituximab, in combination with immune stimulating therapies for the treatment of various cancers, and developing its proprietary exosome technology for the detection and monitoring of cancer. For more information, please visit www.peregrineinc.com.
All Merck KGaA, Darmstadt, Germany news releases are distributed by email at the same time they become available on the EMD Group website. In case you are a resident of the U.S. or Canada please go to www.emdgroup.com/subscribe to register again for your online subscription of this service as our newly introduced geo-targeting requires new links in the email. You may later change your selection or discontinue this service.
About the Life Science Business of Merck KGaA, Darmstadt, Germany
The life science business of Merck KGaA, Darmstadt, Germany, which operates as MilliporeSigma in the U.S. and Canada, has 19,000 employees and 65 manufacturing sites worldwide, with a portfolio of more than 300,000 products enabling scientific discovery. Udit Batra is the global chief executive officer of MilliporeSigma.
Merck KGaA, Darmstadt, Germany completed its $17 billion acquisition of Sigma-Aldrich in November 2015, creating a leader in the $125 billion global life science industry.
Merck KGaA, Darmstadt, Germany is a leading company for innovative and top-quality high-tech products in healthcare, life science and performance materials. The company has six businesses -- Biopharmaceuticals, Consumer Health, Allergopharma, Biosimilars, Life Science and Performance Materials -- and generated sales of EUR 15.0 billion in 2016. Around 50,000 employees work in 66 countries to improve the quality of life for patients, to foster the success of customers and to help meet global challenges.
Merck KGaA, Darmstadt, Germany is the world's oldest pharmaceutical and chemical company -- since 1668, the company has stood for innovation, business success and responsible entrepreneurship. Holding an approximately 70 percent interest, the founding family remains the majority owner of the company to this day. The company holds the global rights to the name and the trademark "Merck" internationally except for the United States and Canada, where the company operates as EMD Serono, MilliporeSigma and EMD Performance Materials.
Like the positive thinking and most likely true.
Just feeling like not a whole lot about to happen between now and
Tues. Soooo enjoy the weekend all. HMD
Happy RED, WHITE, and BLUE to all.
OH and let's us not to forget a whole lot of GREEN
Good luck Peregriners!!
I have a hard time connecting with your answer.
We will get what we usually get, who ever is holding and this changes will respond in the favorable light, while others with their negativity will respond in their usual negative tones.
Lets go a little deeper if we could BDU. You seem to have a grudge against PPHM and grinding your ax ain't going to get you anywhere around here. People are holding strong, (all in) or just a few thousand out of curiosity. Personally I want this science to be recognized for what it is. I'm a long long with patience to see this through. I wont starve or loose my home if the bureaucrats get their way...Either way if the science is what it's proclaimed to be and PPHM owns all IP rights...Well what does it all come down to???
Legal battles to the end?
But any way, back to you...What is your position??
Me thinks not today!!!
No predictions as to what that formation might mean, but I like the closing vol.
The structure and added comment is for entertainment purposes only :)
OH lookey wookey... the volume on the min. chart shows the football ready to be kicked thru the goal post....
I know, I know oh, negative ones out there..... lucy pulls the football away.... maybe not!!
Another reminder..............
Your vocabulary is limited and moderators need to be reminded that repeated post are considered duplicate. Copy and past ku.
In order to understand you must be able to read sign
get some horses in the race.. and get a new jockey, trainer and owner.
Maybe you really need to remind the board every hr. as others do, so we don't forget....OR maybe trying to deter retail.
Might work MAYBE!! It won't stop the like of Blackrock though!!
Sentiment rising again today....lOOking favorable?
0.81.......What does it all mean! Good week ahead maybe.
It's tight
But building with some volume maybe we see .5999 close
Late on the response
But I hope once will suffice.
Very thin today....Maybe power hr.?!?! :0
Yes, that's why I only say only "coat-tails."
I would feel lucky is we can only catch a ride for now.
BUT.....we know how top thinks, They want to be the top hat!!
EDIT: ADD.....OH, OH, here is the wick again.
AZ's gonna be ahead of the pack....I'm thinking coat tails, maybe!!
Got yeah
Understood...seeing a fuse on the daily
NO?????
Previous Close 0.6027
Open 0.6200
OK.... Fill the gap and lets move on!!!
I've got that match...looking for a wick, show me one.
Maybe even a deep re-test to .57 forming a nice W and off we go.
A rev. head and shoulder may be for real .
Feels like leaks (for the good) and some not liking it!!
Anyway (a certain poster) never did have a good word regardless of what was transpiring.
Gawd....I was like a 24 hrs. on my call yesterday....Only two of us agreeing on that ext.
I agree biopharm, as wookie alluded to earlier we will know and recognize when something is leaking, I actually believe the strange trading and the info being made available is already moving to secure another 180 days in our favor.
Exactly what PPHM presented to NASDAQ appeal team
Roger that!!
Bad call, so instead of the steak, it will be steak hamburg!
Maybe fillet pigton and kipper stacks (surf and turf) for fri. :-0
I'll be the first to say PPHM gets the extension!!
As we step'n into the close looking for .62....how's that for
the ballz.
EDIT: AND....880K vol. for the close.
Somebody want to call it!!
In 3....
It's a good thing....we don't need any gaps.